Karen Page
Pfizer (United States)(US)
Publications by Year
Research Areas
Dermatology and Skin Diseases, Asthma and respiratory diseases, IL-33, ST2, and ILC Pathways, Inflammatory Bowel Disease, Microscopic Colitis
Most-Cited Works
- → Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals(2020)747 cited
- → A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results(2021)185 cited
- → Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study(2015)152 cited
- → Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers(2021)92 cited
- → Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study(2017)91 cited
- → The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF‐06700841) in Healthy Subjects and Patients With Plaque Psoriasis(2017)91 cited
- → Matrix metalloproteinase-12 is a therapeutic target for asthma in children and young adults(2010)68 cited
- → Discovery of Isoquinolinone Indole Acetic Acids as Antagonists of Chemoattractant Receptor Homologous Molecule Expressed on Th2 Cells (CRTH2) for the Treatment of Allergic Inflammatory Diseases(2014)54 cited
- → Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis(2020)53 cited
- → Therapeutic activity of an interleukin‐4/interleukin‐13 dual antagonist on oxazolone‐induced colitis in mice(2014)49 cited